VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

Cited by papers we hold 6

• Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches · 2025
  No notice
• Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion · 2024
  No notice
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer · 2021
  No notice
• The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment · 2021
  No notice
• VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy · 2020
  No notice
• Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.